#272 ‒ Rapamycin: potential longevity benefits, surge in popularity, unanswered questions, and more | David Sabatini, M.D., Ph.D. and Matt Kaeberlein, Ph.D.
“[Rapamycin] is the most robust and reproducible drug that we know about today for impacting not only longevity, but to the extent that we can measure various metrics of healthspan in complex animals, rapamycin also seems to positively impact pretty much every aspect of health span that we measure.” —Matt Kaeberlein
#222 ‒ How nutrition impacts longevity | Matt Kaeberlein, Ph.D.
“It’s really important that we be willing to change our beliefs about nutrition and other aspects of health as more data comes in.” —Matt Kaeberlein
The difference between a ‘clean’ drug and a ‘dirty’ drug
This clip is from episode #207 – AMA #35: “Anti-Aging” Drugs — NAD+, metformin, & rapamycin, originally released on May…
#207 – AMA #35: “Anti-Aging” Drugs — NAD+, metformin, & rapamycin
“It’s really hard to know, in my view, how important sirtuins are as longevity factors…If we accept that, then it’s difficult to know [the importance of] activation of sirtuins by NAD as a longevity mechanism.” —Matt Kaeberlein
#204 – Centenarians, metformin, and longevity | Nir Barzilai, M.D.
“If you prevent aging and age-related disease, you’re going to compress morbidity, too.” — Nir Barzilai
#171 – Steve Austad, Ph.D.: The landscape of longevity science: making sense of caloric restriction, biomarkers of aging, and possible geroprotective molecules
“I never thought [extending the human lifespan] was going to happen because we got better at treating cancer or we got better at preventing heart disease. I always thought it was going to happen because we would develop something … that would fundamentally change the rate of aging. And we haven’t developed that yet. We’ve got a lot of clues and I think we’re getting closer and closer and closer.” —Steve Austad